Abstract 2906
Background
The incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) has been increasing over recent decades. Lutetium therapy is now established as a treatment with benefit towards progression-free survival (PFS) in patients with metastatic GEP-NETs with median PFS of up to 36 months. However, the effect of 177Lu-DOTATATE on quality of life (QoL) is not yet well understood with few studies evaluating the impact on symptom control and patient function. Our study sought to evaluate the change in QoL for patients with progressive GEP-NETs treated with 177Lu-DOTATATE.
Methods
Our study was conducted as a part of the Phase II open label clinical trial at the Cross Cancer Institute in Edmonton. Patient enrollment started in March of 2014 and is ongoing. Treatment consisted of induction phase of 5.55 GBq administered at four treatments, 10 weeks apart. For patients without toxicity or progression on treatment, a maintenance phase was entered consisting of 2.78 GBq every 6 months for up to 4 years and maximum of 12 total treatments. QoL over 177Lu-DOTATATE treatment was assessed with EORTC QLQ-C30 and QLQ-GI.NET 21 QoL questionnaires at baseline and subsequent to each treatment. Planned interim analysis of QoL was completed in all patients having completed induction therapy. Repeated measures ANOVA was performed. A p value of < 0.05 was considered significant and change in EORTC score of ≥ 5 points was considered to be clinically significant.
Results
In total 85 patients met inclusion criteria for interim analysis: tumor of gastroenteric or pancreatic origin and completion of four 177Lu-DOTATATE treatments. Primary analysis revealed statistically significant change and clinically significant improvement in mean insomnia (36.43 to 25.58), endocrine symptom (20.37 to 14.81) and GI symptom scores (22.28 to 16.67) from baseline to post fourth treatment. Overall global health status was maintained over treatment course with no improvement but also no statistically significant deterioration in QoL.
Conclusions
177Lu-DOTATATE is not only effective in improving PFS for patients with metastatic GEP-NETs but also maintains overall quality of life and importantly provides patients with improvement in specific symptoms such as insomnia, endocrine and GI symptoms.
Clinical trial identification
NCT01876771.
Legal entity responsible for the study
Alberta Health Services.
Funding
Alberta Cancer Foundation, Alberta Heritage Foundation for Medical Research, Canadian Institutes of Health Research, Canada Foundation for Innovation.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract